Methylenedianiline (MDA) Compliance Plan — 29 CFR 1910.1050
Written compliance plan for 4,4'-methylenedianiline (MDA) exposure. PEL 10 ppb TWA; STEL 100 ppb; Action Level 5 ppb. Built for epoxy resin curing operations, polyurethane manufacturing, and chemical synthesis using MDA.
When this template is required
29 CFR 1910.1050 applies to occupational exposure to MDA outside the construction industry, which is covered by 29 CFR 1926.60 (1910.1050(a)(5)). Products that initial monitoring shows cannot release MDA above the action level are exempt from most of the section (1910.1050(a)(2)). PEL: 10 ppb 8-hour TWA; STEL: 100 ppb 15-min; Action Level: 5 ppb. MDA is used in epoxy resin curing, polyurethane manufacturing, and as a chemical intermediate. IARC Group 2B (possible human carcinogen) with evidence of hepatotoxicity in animals; MDA is a liver toxin rather than a bladder carcinogen.
Why this template
Skin absorption route
MDA is readily absorbed through skin — dermal exposure can be a more significant exposure route than inhalation. The plan emphasises skin protection.
Hepatotoxic + carcinogenic
MDA causes liver damage (acute and chronic) and is a probable carcinogen. The 1965 Epping Jaundice outbreak (UK bakers exposed to MDA-contaminated flour) established the acute liver toxicity. Medical surveillance focuses on liver function.
Epoxy curing focus
MDA is a hot-cured epoxy hardener used in high-performance applications (aerospace composites, industrial coatings). The plan addresses the curing operation exposures.
Very low PEL (10 ppb)
The MDA PEL (10 ppb) is among the lowest in Subpart Z, reflecting the substantial hazard. Achieving the PEL requires careful engineering controls.
What you receive
- 4,4'-Methylenedianiline (MDA) Compliance Plan (Word .docx) — written program per (d)-(n)
- Initial exposure determination procedure (PEL: 10 ppb TWA / 100 ppb STEL; Action Level: 5 ppb)
- Air monitoring schedule (initial + periodic + change-triggered)
- Methods of compliance — engineering & work practice controls hierarchy
- Respiratory protection program crosswalk (with 1910.134)
- Medical surveillance protocol (examination by or under the supervision of a licensed physician, blood/biological tests as applicable)
- Regulated area designation procedure (airborne above the PELs, or wherever dermal exposure to MDA can occur)
- Housekeeping and hygiene procedures
- Employee training outline (annual refresher requirement)
- Recordkeeping requirements (exposure: 30 years; medical: employment + 30 years)
- Epoxy curing operations procedure
- Hepatic surveillance (liver function tests)
- Skin exposure controls (dermal absorption route)
How you get it
This document is written and reviewed against the standard it cites, and it is ready now. The download link is emailed as soon as your payment clears.
Revisions included — if something about your operation changes what the document should say, reply to the delivery email and we will amend it.
Who buys this
- Epoxy resin curing (high-temperature curing systems)
- Polyurethane manufacturing (MDA as intermediate)
- Composite manufacturing (epoxy systems)
- Aerospace composites manufacturing
- Chemical synthesis using MDA
Frequently asked
What uses MDA?
Primary uses: (1) Epoxy resin hardener for high-performance applications — aerospace composites, industrial coatings, electronics encapsulants requiring high heat resistance; (2) Polyurethane intermediate — though MDA itself is not in finished polyurethane products; (3) Chemical synthesis intermediate for various dyes and polymers. Total US worker population is small (a few thousand directly exposed).
Why the focus on skin exposure?
MDA is well-absorbed through intact skin — dermal absorption can deliver a significant fraction of total exposure dose, sometimes exceeding inhalation exposure. The plan emphasises chemical-resistant gloves, sleeves, and work practices to prevent skin contact. Skin notation appears on the MDA standard recognizing this route.
What's the medical surveillance protocol?
1910.1050(m)(1)(i) sets five triggers, not one: exposure at or above the action level for 30 or more days a year; dermal exposure to MDA for 15 or more days a year; exposure in an emergency; any employee the employer has reason to believe is being dermally exposed on the paragraph (e)(8) results; and any employee showing signs or symptoms of MDA exposure. The initial examination covers a detailed history (past exposures; drugs, alcohol, tobacco and medication; any history of dermatitis, chemical skin sensitisation or previous hepatic disease); a physical examination including all routine parameters, a skin examination and signs of liver disease; liver function tests and urinalysis; and further tests as the physician considers necessary (1910.1050(m)(2)). Periodic examinations follow at least annually.
Is this commonly enforced?
Less frequently than the major Subpart Z standards (lead, asbestos, Cr(VI)) given the smaller exposed population. However, aerospace composite manufacturing has come under increased OSHA attention, and MDA is a recognized exposure in those operations.
Does this cover composite shop operations?
Yes — composite manufacturing using MDA-cured epoxy resins is a primary use case. Lamination, oven curing, and post-cure operations all can produce MDA exposure. The plan addresses composite shop workflow with the MDA-specific controls overlaid.
Does this cover construction work?
No. 29 CFR 1910.1050 does not apply to the construction industry as defined in 29 CFR 1910.12(b); exposure to MDA in construction is covered by 29 CFR 1926.60 (1910.1050(a)(5)). This plan is written to the general industry standard.